On July 22, Arrowhead Pharmaceuticals rose 19.25% in regular trading, trading at $89.23/share, with turnover of $117 million. The surge was driven by the company announcing that its core drug Plozasiran successfully met primary endpoints in two pivotal late-stage clinical trials.

Specifically, Plozasiran achieved median triglyceride reductions of 79% and 81% in the Shasta-3 and Shasta-4 trials respectively. Notably, the drug demonstrated a 100% risk reduction in acute pancreatitis events among high-risk patient populations, while maintaining a stable safety profile with no new safety signals observed. Plozasiran had previously received EU marketing authorization under the brand name Redemplo for the treatment of familial chylomicronemia syndrome. The simultaneous release of multiple positive datasets further broadens the drug's indication prospects in the cardiovascular metabolic disease space, significantly boosting investor confidence in the company's commercial outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)